PCPA is the peak body for private practice cancer specialists – medical oncologists, haematologists and radiation oncologists – recognised by government, payers and patient groups.

---

PCPA Achievements

Our Outcomes

Since 2007, the Private Cancer Physicians of Australia (PCPA) has been a high impact peak
body that advocates for cancer patients. The medical oncologists, haematologists and radiation oncologists who are our members and care for Australian cancer patients within the private healthcare system, want to ensure the ecosystem remains robust and resilient.

Our work has never been more important. We need your help to ensure the cancer patient voice in Canberra and those that treat them, is heard and actioned.

Together with our patient advocacy groups and clinical stakeholders, we lead the engagement with the nation’s decision-makers to ensure they prioritise the needs of Australians living with cancer. Recent examples of our work include:

• PCPA delegate at the Parliament House roundtable to advocate for a Bridging Fund Coalition
• Leading the engagement regarding the Inquiry into Specialist fees with our active Canberra program
• PCPA involvement in the Senate Community Affairs inquiry into treatment access for rare cancers, with a joint submission across Cancer Council Australia, MOGA, COSA and CNSA
• The formation of the PCPA Cellular Therapies Alliance (CTA), will drive our haematology focus and advocacy for access to CART-cell therapies in the private sector is achieved
• Expanding access to key oncology medicines and genomics
• Voicing our need for transparency and action in accelerating the approval of medicines and diagnostics through improved HTA process
• Advocating for bipartisan support for policies aimed at reducing the financial toxicity of the cancer patients’ treatment journey
• Seeking (& being granted) an extension of 6 months for MBS item numbers for TeleHealth for patients requiring phone consults with their specialists during the COVID19 pandemic.
• Ensuring cancer patient navigators are front and centre of the National Cancer Plan
• Ring-fencing cancer patients – and their chemotherapy treatments – from the Special Pricing Arrangement (SPA) reforms
• Extending MBS to subcutaneous chemotherapy treatments
• Achieving our key objectives for cancer patients out of the long-running MBS review

We have worked hard to harness funding and meaningful policy outcomes and our track record is reflected in our high political capital with all sides of politics.